Piper Sandler reiterates Abivax stock rating on trial data
Piper Sandler reiterated an Overweight rating and $175 price target for Abivax (ABVX) after positive trial data. The firm highlighted obefazimod's strong endoscopic-remission profile in inflammatory bowel disease. ABVX shares have fallen 30% since August, trading at $94.21. Analysts' price targets range from $142 to $181. Goldman Sachs initiated coverage with a Buy rating and $155 target, citing obefazimod's potential in ulcerative colitis.
How this was made
The 30-second read
Why it matters
Analyst upgrades and higher price targets suggest a short‑term bullish bias, but execution risk remains.
Market read
New clinical data could drive a near‑term rally in ABVX and influence sentiment in the biotech space.
What to watch
Potential competition and reimbursement challenges may temper the rally.
Background
The article reports analyst coverage updates following fresh Phase 3‑type trial data for Abivax's obefazimod in ulcerative colitis.
Ticker impact
Piper Sandler reiterated Overweight and a $175 price target after new ABTECT-Maintenance trial data showed higher endoscopic improvement and remission rates for obefazimod.
potential upside as market prices in improved efficacy data
The new trial results are a primary disclosure and directly support a higher valuation, likely prompting buying pressure.
Market effects
Strengthens the IBD biotech sector as a late‑stage trial shows efficacy.
U.S. biotech investors may react positively.
Limited to investors tracking clinical‑trial outcomes.
Counterpoint
If the data do not translate into regulatory approval, the upside could be limited.
Key entities
- analystPiper Sandler
Reiterated Overweight rating and $175 target.
- analystGoldman Sachs
Initiated coverage with a buy rating and $155 target.
